Results 131 to 140 of about 19,271 (221)

The Effect of Porcine Orexin a on Glucose-Dependent Insulinotropic Polypeptide Plasma Concentrations in Pigs

European Journal of Inflammation, 2010
The orexigenic system was discovered in 1998. It consists of two neuropeptides, Orexin A and Orexin B. Researchers have focused more on Orexin A, since its intracerebroventricular injection into the lateral ventricle of the rat's brain causes an increase
P. Papakonstantinou, N. Tziris, D. Kapoukranidou, A. Gotzamani-Psarrakou, C.H.R. Tsonidis, M.N. Patsikas, G. Papazoglou   +6 more
doaj   +1 more source

Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin‐Based Therapy and Referred or Not to a Weight Management Clinic: A Single‐Center Retrospective Analyses

Obesity Science &Practice, Volume 12, Issue 1, February 2026.
ABSTRACT Background Incretin therapies yield strong metabolic improvements, but whether adding a weight‐management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear. Objective Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes
Kathleen M. Robinson, Stephanie H. Rodriguez, Cyril Pedagarla, Patrick Ten Eyck, Marcelo Correia, Ayotunde Dokun   +5 more
wiley   +1 more source

Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice

Clinical Medicine Insights: Endocrinology and Diabetes, 2019
Hypersecretion and alterations in the biological activity of the incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), have been postulated as contributing factors in the development of obesity-related diabetes.
RA Perry, SL Craig, MT Ng, VA Gault, PR Flatt, N Irwin   +5 more
doaj   +1 more source

Development of the Weight and Emotions Scale (WES)

Obesity Science &Practice, Volume 12, Issue 1, February 2026.
ABSTRACT Objective Obesity and overweight are associated with significant psychosocial burden. Existing patient‐reported outcome (PRO) measures only assess a subset of emotion‐related concepts that are relevant to individuals living with these conditions.
Chisom Kanu, Miriam Kimel, Iris Goetz, Lisa M. Neff, Kristina S. Boye, Marissa Stefan, Jessica Jordan   +6 more
wiley   +1 more source

Características de acción de las exendinas sobre el transporte y metabolismo hepático y muscular de la glucosa, en estado normal y diabético tipo 2 [PDF]

, 2008
Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología.
Arnés Pérez, Luis
core   +1 more source

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v ...
Bruna Bernar Dias, Laura Ben Olivo, Bibiana Verlindo de Araújo   +2 more
wiley   +1 more source

Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide

Journal of Diabetes, Volume 18, Issue 2, February 2026.
Network meta‐analysis comparing the effects of tirzepatide, semaglutide, and placebo on body weight reduction and glycemic outcomes in adults with overweight or obesity. ABSTRACT Introduction Pharmacological therapies are recommended for individuals with obesity.
Julia C. Bernardi, Deivyd V. S. Cavalcante, Ramon Huntermann, Maria E. Molinari, Luana Z. Zanon, Jacinthe Khater, Victor A. Gomez, Caroline O. Fischer‐Bacca   +7 more
wiley   +1 more source

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1116-1125, February 2026.
Abstract Aims To understand the importance and potential impacts of reaching a lower weight or body mass index (BMI) from the perspectives of people with type 2 diabetes (T2D) across BMI levels. Materials and methods A cross‐sectional survey, informed by qualitative interviews, was administered to a sample representative of the US T2D population by BMI.
Melissa M. Ross, Sarah Mulnick, Kristina S. Boye, Ashley Samuelson, Vivian Thuyanh Thieu, Christine Longuet, Jennifer Glass, Meredith M. Hoog   +7 more
wiley   +1 more source